US20020128172A1 - Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases - Google Patents
Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases Download PDFInfo
- Publication number
- US20020128172A1 US20020128172A1 US09/969,408 US96940801A US2002128172A1 US 20020128172 A1 US20020128172 A1 US 20020128172A1 US 96940801 A US96940801 A US 96940801A US 2002128172 A1 US2002128172 A1 US 2002128172A1
- Authority
- US
- United States
- Prior art keywords
- treatment
- bladder
- modulator
- composition according
- conditions associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Definitions
- This invention relates to treatment of conditions associated with bladder hypersensitivity, and conditions associated with a poorly functioning bladder.
- WO 91/16045 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT 4 receptor antagonists in the treatment of atrial arrhythmias and stroke.
- Metoclopramide has been shown to be effective in treating a poorly functioning bladder, (Scand. J. Urology and Nephrology, 13:79-82 (1979) but this has not been specifically linked to any known action of metoclopramide.
- a compound which acts as an antagonist at 5-HT 4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT 4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.
- IBS irritable bowel syndrome
- 5-HT 4 modulator is used to denote antagonists and agonists.
- the invention therefore provides a method for the treatment and/or prophylaxis of conditions associated with bladder hypersensitivity and conditions associated with a poorly functioning bladder in mammals, including humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis, an effective and/or prophylactic amount of a 5-HT 4 modulator.
- 5-HT 4 modulators may be identified according to standard methods, such as those described hereinafter, and that described in Naunyn-Schmiedeberg's Arch Pharmacol. 342,619-622.
- 5-HT 4 receptor antagonists examples include ICS 205-930 (tropisetron-Sandoz), R 50 595 (Janssen), which is described in FR 76530 and Eur.J. Pharmacol., 181 119-125 (1990), and SDZ 205-557, which is described by K. H. Buchheit and R. Gamse in Naunyn-Schmiedeberg's Arch. Pharmacol., 343 (Suppl.), R101 (1991).
- DAU 6285 Naunyn-Schmiedeberg's Arch. Pharmacol, 345; 264-269 (1992) and RS 23597-190 (Syntex-British Pharmacology Society Meeting, September 1992).
- EP-A-501322 (Glaxo Group Limited) describes indole derivatives having 5-HT 4 receptor antagonist activity and reports 5-HT 4 receptors are believed to be associated with conditions involving inter alia the urinary tract (e.g. urinary incontinence).
- Examples of 5-HT 4 receptor agonists include cisapride, renzapride and zacopride.
- the 5-HT 4 modulator is more potent at 5-HT 4 receptors than at 5-HT 3 receptors.
- the 5-HT 4 modulator is in substantially pure pharmaceutically acceptable form.
- the administration of the 5-HT 4 modulator may be by way of oral, sublingual, transdermal or parenteral administration.
- an amount effective to treat the disorder hereinbefore described depends on the usual factors such as the nature and severity of the disorder being treated and the weight of the mammal.
- a unit dose will normally contain 0.1 to 50 mg for example 0.5 to 10 mg, of the 5-HT 4 modulator.
- Unit doses will normally be administered once or more than once a day, for example 2, 3, or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 50 mg, for example 0.1 to 5 mg, that is in the range of approximately 0.001 to 1 mg/kg/day, more usually 0.005 to 0.2 mg/kg/day.
- the 5-HT 4 modulator is administered in the form of a unit-dose composition, such as a unit dose oral or parenteral composition.
- compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
- Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
- the tablets may be coated according to well known methods in the art.
- Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
- Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
- Suitable lubricants include, for example, magnesium stearate.
- Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
- These solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
- Oral liquid preparations may be the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
- suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate
- Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
- fluid unit dose forms are prepared containing the 5-HT 4 modulator and a sterile vehicle.
- the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
- Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
- compositions will usually be accompanied by written or printed directions for use in the treatment concerned.
- the present invention also provides the use of a 5-HT 4 modulator in the manufacture of a medicament for. use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity. Such treatment and/or prophylaxis may be carried out as hereinbefore described.
- the present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity, which comprises a 5-HT 4 modulator, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity which comprises a 5-HT 4 modulator, and a pharmaceutically acceptable carrier.
- Such compositions may be prepared in the manner as hereinbefore described.
- guinea-pigs Male guinea-pigs, weighing 250-400 g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3 cm long, are obtained from the distal colon region. These are suspended under a 0.5 g load in isolated tissue baths containing Krebs solution bubbled with 5% CO 2 in O 2 and maintained at 37° C. In all experiments, the Krebs solution also contains methiothepin 10 ⁇ 7 Mn and granisetron 10 ⁇ 6 M to block effects at 5-HT 1 , 5-HT 2 and 5-HT 3 receptors.
- a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 40-70% maximum(10-9M approx).
- the tissue is then alternately dosed every 15 min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP).
- DMPP dimethylphenylpiperazinium
- increasing concentrations of a putative 5-HT 4 modulator are then added to the bathing solution. The effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP.
- IC 50 values are determined, being defined as the concentration of antagonist or agonist which reduces or increases the contraction by 50%.
- a compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT 4 receptor antagonist and a compound which increases the response to 5-HT but not to DMPP is believed to act as a 5-HT 4 receptor agonist.
- Rat oesophageal tunica muscularis mucosae is set up according to Baxter et. al. Naunyn-Schmiedeberg's Arch. Pharmacol., 343, 439-446 (1991).
- the inner smooth muscle tube of the muscularis mucosae is isolated and mounted for isometric tension recording in oxygenated (95% O 2 /5% CO 2 ) Tyrodes solution at 37°. All experiments are performed in pargyline pretreated preparations (100 ⁇ M for 15 min followed by washout) and in the presence of ***e (30 ⁇ M). Relaxant responses to 5-HT are obtained after pre-contracting the oesophagus tissue with carbachol (3 ⁇ M).
Abstract
A compound which acts as an antagonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.
Description
- This invention relates to treatment of conditions associated with bladder hypersensitivity, and conditions associated with a poorly functioning bladder.
- European Journal of Pharmacology 146 (1988), 187-188, and Naunyn-Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410, describe a non classical 5-hydroxytryptamine receptor, now designated the 5-HT 4 receptor, and that tropisetron (ICS 205-930), which is also a 5-HT3 receptor antagonist, acts as an antagonist at this receptor and metoclopramide is an agonist at this receptor.
- WO 91/16045 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT 4 receptor antagonists in the treatment of atrial arrhythmias and stroke.
- Metoclopramide has been shown to be effective in treating a poorly functioning bladder, (Scand. J. Urology and Nephrology, 13:79-82 (1979) but this has not been specifically linked to any known action of metoclopramide.
- There are reports in the literature of 5-HT 4 receptors potentiating contractions in human bladder (Br. J. Pharmacol, 61, 115P) and inhibiting contractions in monkey bladder (2nd International Symposium on Serotonin, Houston, September 1992, page 86).
- We have now discovered that a compound which acts as an antagonist at 5-HT 4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy. When used herein the term ‘5-HT4 modulator’ is used to denote antagonists and agonists.
- The invention therefore provides a method for the treatment and/or prophylaxis of conditions associated with bladder hypersensitivity and conditions associated with a poorly functioning bladder in mammals, including humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis, an effective and/or prophylactic amount of a 5-HT 4 modulator.
- 5-HT 4 modulators may be identified according to standard methods, such as those described hereinafter, and that described in Naunyn-Schmiedeberg's Arch Pharmacol. 342,619-622.
- Examples of 5-HT 4 receptor antagonists include ICS 205-930 (tropisetron-Sandoz), R 50 595 (Janssen), which is described in FR 76530 and Eur.J. Pharmacol., 181 119-125 (1990), and SDZ 205-557, which is described by K. H. Buchheit and R. Gamse in Naunyn-Schmiedeberg's Arch. Pharmacol., 343 (Suppl.), R101 (1991). DAU 6285 (Naunyn-Schmiedeberg's Arch. Pharmacol, 345; 264-269 (1992) and RS 23597-190 (Syntex-British Pharmacology Society Meeting, September 1992).
- EP-A-501322 (Glaxo Group Limited) describes indole derivatives having 5-HT 4 receptor antagonist activity and reports 5-HT4 receptors are believed to be associated with conditions involving inter alia the urinary tract (e.g. urinary incontinence).
- Examples of 5-HT 4 receptor agonists include cisapride, renzapride and zacopride.
- In one aspect, the 5-HT 4 modulator is more potent at 5-HT4 receptors than at 5-HT3 receptors.
- Preferably, the 5-HT 4 modulator is in substantially pure pharmaceutically acceptable form.
- The administration of the 5-HT 4 modulator may be by way of oral, sublingual, transdermal or parenteral administration.
- An amount effective to treat the disorder hereinbefore described depends on the usual factors such as the nature and severity of the disorder being treated and the weight of the mammal. However, a unit dose will normally contain 0.1 to 50 mg for example 0.5 to 10 mg, of the 5-HT 4 modulator. Unit doses will normally be administered once or more than once a day, for example 2, 3, or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 50 mg, for example 0.1 to 5 mg, that is in the range of approximately 0.001 to 1 mg/kg/day, more usually 0.005 to 0.2 mg/kg/day.
- For oral or parenteral administration, it is greatly preferred that the 5-HT 4 modulator is administered in the form of a unit-dose composition, such as a unit dose oral or parenteral composition.
- Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
- Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.
- Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
- These solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
- Oral liquid preparations may be the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
- Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
- For parenteral administration, fluid unit dose forms are prepared containing the 5-HT 4 modulator and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
- As is common practice, the compositions will usually be accompanied by written or printed directions for use in the treatment concerned.
- The present invention also provides the use of a 5-HT 4 modulator in the manufacture of a medicament for. use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity. Such treatment and/or prophylaxis may be carried out as hereinbefore described.
- The present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity, which comprises a 5-HT 4 modulator, and a pharmaceutically acceptable carrier. Such compositions may be prepared in the manner as hereinbefore described.
- 5-HT 4 Modulator Activity
- 1) Guinea Pig Colon
- Male guinea-pigs, weighing 250-400 g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3 cm long, are obtained from the distal colon region. These are suspended under a 0.5 g load in isolated tissue baths containing Krebs solution bubbled with 5% CO 2 in O2 and maintained at 37° C. In all experiments, the Krebs solution also contains methiothepin 10−7Mn and granisetron 10−6M to block effects at 5-HT1, 5-HT2 and 5-HT3 receptors.
- After construction of a simple concentration-response curve with 5-HT, using 30 s contact times and a 15 min dosing cycle, a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 40-70% maximum(10-9M approx). The tissue is then alternately dosed every 15 min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP). After obtaining consistent responses to both 5-HT and DMPP, increasing concentrations of a putative 5-HT 4 modulator are then added to the bathing solution. The effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP.
- From this data, IC 50 values are determined, being defined as the concentration of antagonist or agonist which reduces or increases the contraction by 50%. A compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT4 receptor antagonist and a compound which increases the response to 5-HT but not to DMPP is believed to act as a 5-HT4 receptor agonist.
- 2) Rat Oesophagus
- Rat oesophageal tunica muscularis mucosae is set up according to Baxter et. al. Naunyn-Schmiedeberg's Arch. Pharmacol., 343, 439-446 (1991). The inner smooth muscle tube of the muscularis mucosae is isolated and mounted for isometric tension recording in oxygenated (95% O 2/5% CO2) Tyrodes solution at 37°. All experiments are performed in pargyline pretreated preparations (100 μM for 15 min followed by washout) and in the presence of ***e (30 μM). Relaxant responses to 5-HT are obtained after pre-contracting the oesophagus tissue with carbachol (3 μM).
Claims (10)
1. A method for the treatment and/or prophylaxis of conditions associated with bladder hypersensitivity and conditions associated with a poorly functioning bladder in mammals, including humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis, an effective and/or prophylactic amount of a 5-HT4 modulator.
2. The use of a 5-HT4 modulator in the manufacture of a medicament for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity.
3. A pharmaceutical composition for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity, which comprises a 5-HT4 modulator, and a pharmaceutically acceptable carrier.
4. A method, use or composition according to claim 1 , 2 or 3 wherein the 5-HT4 modulator is a 5-HT4 receptor antagonist.
5. A method, use or composition according to claim 4 for the treatment of urinary incontinence.
6. A method, use or composition according to claim 5 for the treatment of urinary incontinence associated with irritable bowel syndrome.
7. A method, use or composition according to claim 4 , 5 or 6 wherein 5-HT4 receptor antagonist is R 50 595, SDZ 205-557, DAU 6285, RS 23597-190 or a compound described in relation to EP-A-501322 (Glaxo Group Limited).
8. A method, use or composition according to claim 1 , 2 or 3 wherein the 5-HT4 modulator is a 5-HT4 receptor agonist.
9. A method, use or composition according to claim 8 for the treatment of urinary bladder hypoactivity following prostectomy.
10. A method, use or composition according to claim 8 or 9 wherein 5-HT4 receptor agonist is cisapride, renzapride or zacopride.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/969,408 US20020128172A1 (en) | 1991-12-21 | 2001-10-02 | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
| US10/260,323 US6750195B2 (en) | 1991-12-21 | 2002-09-27 | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9127184.1 | 1991-12-21 | ||
| GB9127185.8 | 1991-12-21 | ||
| GB919127185A GB9127185D0 (en) | 1991-12-21 | 1991-12-21 | Pharmaceuticals |
| GB919127184A GB9127184D0 (en) | 1991-12-21 | 1991-12-21 | Pharmaceuticals |
| GB9219354.9 | 1992-09-12 | ||
| GB929219354A GB9219354D0 (en) | 1992-09-12 | 1992-09-12 | Pharmaceuticals |
| US95964297A | 1997-10-28 | 1997-10-28 | |
| US71073300A | 2000-11-09 | 2000-11-09 | |
| US09/969,408 US20020128172A1 (en) | 1991-12-21 | 2001-10-02 | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US71073300A Continuation | 1991-12-21 | 2000-11-09 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/260,323 Continuation US6750195B2 (en) | 1991-12-21 | 2002-09-27 | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20020128172A1 true US20020128172A1 (en) | 2002-09-12 |
Family
ID=27517096
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/969,408 Abandoned US20020128172A1 (en) | 1991-12-21 | 2001-10-02 | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
| US10/260,323 Expired - Fee Related US6750195B2 (en) | 1991-12-21 | 2002-09-27 | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/260,323 Expired - Fee Related US6750195B2 (en) | 1991-12-21 | 2002-09-27 | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US20020128172A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050261344A1 (en) * | 2002-08-14 | 2005-11-24 | Jones Charles R | Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| US20060094715A1 (en) * | 2002-05-16 | 2006-05-04 | Levy Finn O | 5-Ht4 receptor antagonists for the treatment of heart failure |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1104289T3 (en) * | 1998-08-21 | 2006-05-15 | Novartis Ag | New oral formulations for 5-HT 4 agonists or antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR76530E (en) | 1959-11-10 | 1961-11-03 | Gillet Roquigny Ets | Cremona and its garnishes |
| US5362756A (en) | 1989-02-20 | 1994-11-08 | Riviere Pierre J M | Use of fedotozine in the treatment of functional states of intestinal obstructions |
| GB9009389D0 (en) | 1990-04-26 | 1990-06-20 | Smith Kline French Lab | Treatment |
| CA2044854A1 (en) | 1990-07-19 | 1992-01-20 | Hong-I Chen | Method for preventing or treating urinary incontinence |
| GB9103862D0 (en) | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| CA2082415A1 (en) | 1991-03-07 | 1992-09-08 | Daniel P. Becker | Meso-azacyclic aromatic acid amides and esters as novel serotonergic agents |
| JPH06509574A (en) | 1991-08-03 | 1994-10-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5-HT↓4 receptor antagonist |
| JPH06510283A (en) | 1991-08-20 | 1994-11-17 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5-HT4 receptor antagonist |
| CA2118798A1 (en) | 1991-09-12 | 1993-03-18 | Francis D. King | Azabicyclic compounds as 5-ht4 receptor antagonists |
| CZ283619B6 (en) | 1991-09-12 | 1998-05-13 | Smithkline Beecham P.L.C | Benzoic acid derivatives, process of their preparation and pharmaceutical composition containing thereof |
| EP0609278A1 (en) | 1991-10-24 | 1994-08-10 | Smithkline Beecham Plc | Imidazopyridines and indolizines as 5-ht 4 antagonists |
-
2001
- 2001-10-02 US US09/969,408 patent/US20020128172A1/en not_active Abandoned
-
2002
- 2002-09-27 US US10/260,323 patent/US6750195B2/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060094715A1 (en) * | 2002-05-16 | 2006-05-04 | Levy Finn O | 5-Ht4 receptor antagonists for the treatment of heart failure |
| US20090169545A1 (en) * | 2002-05-16 | 2009-07-02 | Serodus As | 5-ht4 receptor antagonists for the treatment of heart failure |
| US8829028B2 (en) | 2002-05-16 | 2014-09-09 | Serodus As | 5-HT4 receptor antagonists for the treatment of heart failure |
| US20050261344A1 (en) * | 2002-08-14 | 2005-11-24 | Jones Charles R | Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
Also Published As
| Publication number | Publication date |
|---|---|
| US6750195B2 (en) | 2004-06-15 |
| US20030045452A1 (en) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2214532T3 (en) | USE OF DEXTRORPHAN OR DEXTROMETORPHAN FOR THE TREATMENT OF URINARY INCONTINENCE. | |
| WO1994002150A1 (en) | Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity | |
| EP0176689B1 (en) | Benzopyran compounds for the treatment of smooth muscles contraction | |
| SK281603B6 (en) | Use of serotonin antagonists (5ht3) for treating fibromyalgia | |
| EP0617620B1 (en) | Use of 5-ht4 - antagonists for the manufacture of a medicament for the treatment of urinary incontinence | |
| US5663184A (en) | Methods of inhibiting CNS problems in post-menopausal women | |
| HUT71477A (en) | Pharmaceutical compositions for increasing libido in post-menopausal women containing 2-phenyl-3-aroil-benzothiophene derivatives and process for their preparation | |
| IE912237A1 (en) | Pharmaceutical preparations | |
| CA2081344C (en) | Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke | |
| US6750195B2 (en) | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases | |
| WO1994000113A2 (en) | Medicaments containing 5-ht4 receptor antagonists | |
| US5763459A (en) | Medicaments for the treatment of anxiety | |
| IE83342B1 (en) | Use of a 5-HT4-receptor antagonists in the treatment of atrial fibrillation, including the prevention of stroke | |
| EP0173039A2 (en) | Use of xanthine and thioxanthine derivatives for the preparation of medicaments | |
| US5049588A (en) | Novel treatment for ischemia using an aminotetralin | |
| CA2158354C (en) | Use of granisetron for the treatment of post-operative nausea and vomiting | |
| US5162375A (en) | Treatment of neuronal degeneration with 5HT1A agonists | |
| US4789679A (en) | Method for treating incontinence | |
| WO1993014745A1 (en) | Use of 5-ht4 receptor antagonists as medicaments for treating migraine | |
| Cohen et al. | LY353433, a potent, orally effective, long-acting 5-HT (4) receptor antagonist: comparison to cisapride and RS23597-190. | |
| WO2000037082A1 (en) | Use of 5-ht7 receptor antagonists for treating neuronal degeneration resulting from ischemic events | |
| WO1997036586A1 (en) | Treatment or prophylaxis of diarrhoea | |
| JPH02223523A (en) | Drug for medical treatment of anxiety neurosis and insomnia | |
| WO1993009778A2 (en) | Use of brl 38227 for the treatment and prophylaxis of hyperlipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |